Elizabeth Reid Coughlin Sells 1,554 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the completion of the sale, the insider owned 34,024 shares in the company, valued at $16,501,640. The trade was a 4.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Axon Enterprise Stock Performance

Shares of AXON traded down $15.06 during mid-day trading on Monday, reaching $471.06. The company had a trading volume of 941,797 shares, compared to its average volume of 1,098,205. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $37.97 billion, a P/E ratio of 189.18, a PEG ratio of 8.84 and a beta of 1.45. The stock has a 50 day moving average of $408.04 and a two-hundred day moving average of $491.56.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. During the same quarter in the prior year, the business earned $1.47 earnings per share. The company’s revenue was up 33.7% compared to the same quarter last year. On average, analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AXON has been the topic of a number of recent research reports. Wall Street Zen upgraded Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. UBS Group lowered their price target on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings upgraded Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, Robert W. Baird set a $800.00 price objective on Axon Enterprise in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AXON. Brighton Jones LLC purchased a new position in Axon Enterprise in the fourth quarter valued at $480,000. NewEdge Advisors LLC boosted its holdings in Axon Enterprise by 41.1% in the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after purchasing an additional 668 shares during the period. Empowered Funds LLC boosted its holdings in Axon Enterprise by 8.4% in the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after purchasing an additional 157 shares during the period. Woodline Partners LP boosted its holdings in Axon Enterprise by 40.6% in the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in Axon Enterprise in the second quarter valued at $284,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.